Oral anticoagulation (OAC) is commonly prescribed to patients with atrial brillation, venous thromboembolism (VTE), and mechanical heart valves (MHVs) for primary and secondary thromboembolism prevention. When patients require surgery or an invasive procedure, "bridging" anticoagulants (eg, enoxaparin) are commonly administered during the period of OAC interruption to reduce thromboembolic risk. This practice stems from small observational studies and expert opinion, which in uenced several clinical guidelines despite the lack of high-quality evidence. Although prospective randomized trials of periprocedural bridging in patients with VTE and MHVs are lacking, available evidence is consistent with ndings from the BRIDGE trial, which guides the following general recommendations: (1) avoid unnecessary periprocedural interruptions of OAC, especially for low bleeding risk procedures; (2) avoid the administration of periprocedural bridging anticoagulation in patients with low to moderate thromboembolic risk; (3) in patients with high thromboembolic risk, individually assess the patient-speci c and procedure-speci c bleeding risks versus thromboembolic risks.
The "Things We Do for No Reason" (TWDFNR) series reviews practices that have become common parts of hospital care but that may provide little value to our patients. Practices reviewed in the TWDFNR series do not represent "black and white" conclusions or clinical practice standards, but are meant as a starting place for research and active discussions among hospitalists and patients. We invite you to be part of that discussion.
Oral anticoagulation (OAC) is commonly prescribed to patients with atrial brillation, venous thromboembolism (VTE), and mechanical heart valves (MHVs) for primary and secondary thromboembolism prevention. When patients require surgery or an invasive procedure, "bridging" anticoagulants (eg, enoxaparin) are commonly administered during the period of OAC interruption to reduce thromboembolic risk. This practice stems from small observational studies and expert opinion, which in uenced several clinical guidelines despite the lack of high-quality evidence. Although prospective randomized trials of periprocedural bridging in patients with VTE and MHVs are lacking, available evidence is consistent with ndings from the BRIDGE trial, which guides the following general recommendations: (1) avoid unnecessary periprocedural interruptions of OAC, especially for low bleeding risk procedures; (2) avoid the administration of periprocedural bridging anticoagulation in patients with low to moderate thromboembolic risk; (3) in patients with high thromboembolic risk, individually assess the patient-speci c and procedure-speci c bleeding risks versus thromboembolic risks.
CASE PRESENTATION
A 75-year-old man with a history of hypertension, diabetes mellitus, and atrial brillation is admitted for surgical repair of a comminuted intertrochanteric left hip fracture. He suffered a mechanical ground-level fall without loss of consciousness. At baseline, he denies any chest pain, dyspnea on exertion, or recent change in his exercise tolerance. A physical examination is notable for stable vital signs, irregular cardiac rhythm, and a shortened and externally rotated left lower extremity with exquisite tenderness to palpation and range of motion. The patient is taking warfarin for stroke prophylaxis based on a CHA 2 DS 2 VaSc score of 4 points. The international normalized ratio (INR) is 1.9 upon admission, and surgery is planned within 48 hours, once the patient is "medically cleared." Will this patient bene t from periprocedural bridging anticoagulation?
WHY YOU MIGHT THINK PERIPROCEDURAL "BRIDGING" ANTICOAGULATION IS HELPFUL
OAC is commonly prescribed to patients with atrial brillation, venous thromboembolism (VTE), and mechanical heart valves (MHVs) for the primary or secondary prevention of thromboembolic events, with more than 35 million prescriptions written annually in the United States alone. 1 Many of these patients will require a temporary interruption of their OAC for surgery or an invasive procedure. 2 As a result, patients may be treated with short-acting, or "bridging," anticoagulants, such as low-molecular-weight heparin (LMWH), to minimize the duration of anticoagulation interruption and theoretically reduce their thromboembolic risk. The rationale for bridging stemmed from small observational studies and expert opinion that perceived the estimated thromboembolic risk to be higher than the estimated bleeding risk. [3] [4] [5] One such example estimated that the VTE risk increased 100-fold postoperatively, whereas heparin administration only doubled the bleeding risk. 3 Furthermore, clinical practice guidelines published from the American Heart Association, American College of Cardiology, European Heart Rhythm Society, and American College of Chest Physicians recommend when and how to initiate bridging anticoagulation. Clinicians have widely adopted these recommendations despite an acknowledged paucity of high-quality supporting evidence. 6, 7 WHY PERIPROCEDURAL "BRIDGING" ANTI-COAGULATION IS MORE HARMFUL THAN HELPFUL Periprocedural Anticoagulation Interruption is Often Not Indicated
Patients undergoing a surgical or invasive procedure may require an interruption of OAC to minimize the periprocedural bleeding risk. The decision to interrupt OAC should generally be based on the procedure-speci c bleeding risk. Procedures with low bleeding risk such as cataract surgery, dermatologic biopsy (including Mohs), arthrocentesis, diagnostic gastrointestinal endoscopy, and cardiac pacemaker implantation can be performed safely without OAC interruption. 5, 7 Despite evidence supporting the safety of periprocedural OAC continuation, unnecessary OAC interruptions remain commonplace and are associated with increased adverse outcomes. 8 The BRUISE CONTROL trial compared uninterrupted OAC to interrupted OAC with periprocedural bridging for cardiac pacemaker or de brillator implantation in a moderate to high thromboembolic risk population. The uninterrupted OAC group experienced signi cantly fewer pocket hematomas, hematoma evacuations, and prolonged hospitalizations (relative risk [RR] 0.19-0.24; P < .05) without signi cantly increased thromboembolic events, highlighting the potential bene ts of this approach. 9 Nevertheless, many surgical and invasive procedures do warrant OAC interruption due to the inherent bleeding risk of the procedure or other logistical considerations. Procedures associated with an increased bleeding risk include urologic surgery (except laser lithotripsy), surgery on highly vascular organs (eg, kidney, liver, spleen), bowel resection, cardiac surgery, and intracranial or spinal surgery. 7 Alternatively, some procedures with acceptably low bleeding risk (eg, colonoscopy) are routinely performed during an OAC interruption due to the fact that a high bleeding risk intervention may be necessary during the procedure (eg, polypectomy). This approach may be preferable when a signi cant amount of preparation is required (eg, bowel preparation) and may be a more ef cient use of healthcare resources by avoiding repeat procedures.
Bridging Anticoagulation Does Not Signi cantly Reduce Thromboembolic Events
Several observational studies and a meta-analysis have demonstrated consistently low thromboembolism event rates without conclusive bene ts from bridging anticoagulation (Table 1). [10] [11] [12] [13] Although these methodologically weak studies and expert consensus have served as the basis for guideline recommendations, the consensus is beginning to change based on results from the BRIDGE trial. 4, 5, 14, 15 BRIDGE was a randomized, double-blind, placebo-controlled trial among patients with atrial brillation (n = 1884) requiring OAC interruption for mostly low-risk, ambulatory surgeries or invasive procedures (eg, gastrointestinal endoscopy, cardiac catheterization). Notably, thromboembolism events were rare, and there was no signi cant difference in thromboembolism events between patients randomized to placebo or bridging with LMWH (0.4% vs 0.3%, respectively; P = .73).
However, the proportion of patients enrolled with the highest thromboembolic risk (ie, CHADS 2 score 5-6 or prior transient ischemic attack and/or stroke) was low, potentially indicating an underestimated bene t in these patients. Major bleeding was signi cantly reduced in patients forgoing bridging anticoagulation (1.3% vs 3.2%; RR 0.41; 95% con dence interval, 0.20-0.78; P = .005), although bleeding occurred more frequently than thromboembolism in both groups.
Even though randomized trials assessing the safety and efcacy of bridging for VTE or MHVs have not been completed, evidence is not entirely lacking. 16, 17 A rigorous observational study limited to a VTE cohort (deep vein thrombosis of upper or lower extremity and/or pulmonary embolism) analyzed the effects of bridging in patients with a surgical or invasive procedure-related OAC interruption. Patients were strati ed according to the American College of Chest Physicians perioperative guideline risk-strati cation schema, and most VTE events (≥93%) occurred more than 12 months prior to OAC interruption. 7 Importantly, the study found a nonsigni cant difference in thromboembolism events between patients who were bridged and those who were not (0.0% vs 0.2%, respectively; P = .56), a very low overall thromboembolism event rate (0.2%), and a lack of correlation between events and risk-strati cation category. 17 In other words, all thromboembolic events occurred in the low-and moderate-risk groups, which include patients who do not warrant bridging under current guidelines. Clinically relevant bleeding occurred in 17 (0.9%) of 1812 patients studied. Notably, 15 (2.7%) of 555 patients receiving bridging suffered clinically relevant bleeding as compared with 2 (0.2%) of 1257 patients forgoing bridging anticoagulation.
The Bleeding Risk of Bridging Anticoagulation Often Outweighs the Potential Bene ts
The early observational studies on LMWH bridging demonstrated that thromboembolic events are infrequent (0.4%-0.9%), whereas major bleeding events occur up to 7 times more often (0.7%-6.7%). [10] [11] [12] The BRIDGE trial demonstrated comparably low thromboembolic events (0.3%). In the patients treated with bridging LMWH, major bleeding (3.2%) occurred 10 times more frequently than thromboembolism.
14 Likewise, in a VTE cohort study, Clark et al. 17 demonstrated "a 17-fold higher risk of bleeding without a signi cant difference in the rate of recurrent VTE" in patients bridged with heparin as compared with those who were not. Considering that recurrent VTE and major bleeding events have similar case-fatality rates, 18 these increases in major bleeding events without reductions in thromboembolic events unmistakably tip the risk-bene t balance sharply towards an increased risk of harm.
WHEN IS BRIDGING ANTICOAGULATION POTENTIALLY HELPFUL?
Acknowledging the lack of prospective clinical trials assessing bridging for VTE or MHVs and the predominance of patients with low and moderate thromboembolic risk enrolled in BRIDGE, it is plausible that patients with a high thromboembolic risk (eg, mechanical mitral valve, CHA2DS2VaSc score ≥7, VTE occurrence within 3 months) who are at low risk for bleeding might bene t from bridging. However, until randomized controlled trials are completed in these high-risk populations or risk strati cation systems are derived and validated, the decision to bridge patients with a perceived high thromboembolic risk remains uncertain. Consideration of the patient-speci c and procedure-speci c bleeding risk factors (Table 2) should be weighed against the patient-speci c and procedure-speci c thromboembolic risk factors to derive an individualized risk-bene t assessment.
WHAT SHOULD YOU DO INSTEAD?
First, determine whether periprocedural OAC interruption is necessary for patients on chronic OAC due to atrial brillation, VTE, or MHVs. Avoid unwarranted OAC interruption by discussing the need for OAC interruptions with the surgeon or proceduralist, especially if the surgery is associated with a low bleeding risk and the patient has a high thromboembolic risk. When a periprocedural OAC interruption is justi ed, bridging should be avoided in the majority of patients, especially those with low to moderate thromboembolic risk or increased bleeding risk according to current risk-strati cation schema. 7, 15, 19 Periprocedural management of direct oral anticoagulants (DOACs) is different than that of warfarin. The duration of DOAC interruption is determined by the procedural bleeding risk, drug half-life, and a patient's creatinine clearance. Although the pharmacokinetics of DOACs generally allow for brief interruptions (eg, 24-48 hours), longer interruptions (eg, 96-120 hours) are warranted prior to high bleeding risk procedures, when drug half-life is prolonged (ie, dabigatran), and in patients with renal impairment. Parenteral bridging anticoagulation is not recommended during brief DOAC interruptions, and substituting a DOAC in place of LMWH for bridging is not advised. The 2017 American College of Cardiology Expert Consensus Decision Pathway provides periprocedural OAC interruption guidance for atrial brillation, with many principles applicable to other OAC indications. 15 We developed an institutional guideline that provides clinicians a structured approach to bridging OAC that steers them away from inappropriate bridging and helps them make decisions when evidence is lacking. Shared decision-making represents another effective method for well-informed patients and clinicians to arrive at a mutually agreed upon bridging decision.
RECOMMENDATIONS
• Avoid unnecessary periprocedural interruptions of OAC, especially for procedures with a low bleeding risk.
• Avoid the administration of bridging anticoagulation in patients with low to moderate thromboembolic risk during periprocedural OAC interruptions.
• In patients with a high thromboembolic risk, an individualized assessment of the patient-speci c and procedure-speci c bleeding risks versus the thromboembolic risks is necessary when considering bridging anticoagulation administration.
CONCLUSION
Returning to the opening case, the patient requires an anticoagulation interruption and INR correction prior to surgery. Because the CHA 2 DS 2 VaSc score of 4 does not categorize him as a high thromboembolic risk, bridging anticoagulation should be avoided. In the majority of patients on OAC, bridging anticoagulation does not reduce thromboembolic events and is associated with increased major bleeding. Unnecessary anticoagulation interruptions should be avoided for procedures associated with low bleeding risk. Bridging should not be administered to the majority of patients requiring a periprocedural anticoagulation interruption. Disclosure: The authors report no con icts of interest relevant to this article to disclose.
